Biotie Therapies - Total number of voting rights and capital

New Biotie shares and increase of share capital registered with the Finnish Trade Register

BIOTIE THERAPIES CORP.                  STOCK EXCHANGE RELEASE         17
September 2012 at 8.30 a.m.

Not for release, publication or distribution, directly or indirectly, in whole
or in part, in or into the United States, Australia, Canada, Japan or South
Africa.

New Biotie shares and increase of share capital registered with the Finnish
Trade Register

A total of 65,116,281 new shares offered in Biotie Therapies Corp.'s ("Biotie"
or "Company") directed issues of shares to H. Lundbeck A/S as well as to
institutional and strategic investors announced by the Company on 7 September
2012 and the related share capital increase of EUR 30,000,000.90 has been
registered with the Finnish Trade Register today. The new shares rank pari passu
in all respects with the existing shares of the Company as of their registration
date.

The registered new shares can be traded together with the Company's current
series of shares on the stock exchange list of NASDAQ OMX Helsinki Ltd as of
today.

Following the registration of the new shares with the Finnish Trade Register and
the registration of the share capital increase, the share capital of Biotie is
EUR 195,919,182.85 and the total number of shares 452,710,738. Since 9,169,507
Biotie shares are held by Biotie and its subsidiaries, the number of votes
carried by the outstanding shares is 443,541,231.

In Turku, 17 September 2012

Biotie Therapies Corp.
Timo Veromaa, President and CEO

For further information, please contact:
Virve Nurmi, Investor Relations Manager, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com

www.biotie.com

DISTRIBUTION:
NASDAQ OMX Helsinki Ltd
Main Media



About Biotie

Biotie is a specialized drug development company focused on the development of
drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's disease,
Alzheimer's disease and other cognitive disorders, alcohol and drug dependence
(addiction) and post traumatic stress disorder), and inflammatory and fibrotic
liver disease. The company has a strong and balanced development portfolio with
several innovative small molecule and biological drug candidates at different
stages of clinical development. Biotie's products address diseases with high
unmet medical need and significant market potential.

Biotie has a strategic collaboration with UCB Pharma S.A. covering tozadenant
for Parkinson's disease. The Marketing Authorization Application for Biotie's
most advanced product, SelincroTM (nalmefene) for alcohol dependence was filed
in the EU by our partner H. Lundbeck A/S and was accepted for review by the
European Medicines Agency in December 2011. Biotie shares are listed on NASDAQ
OMX Helsinki Ltd.




[HUG#1641422]